Kate Wills
Seminars
Tuesday 9th March 2027
Enhertu Now – The Power of the Patient Voice & Advocacy to Bring ADC Drugs to Frontline Treatments for Cancer
8:15 am
- Advancing next-generation dual-payload ADCs to address traditional challenges like drug resistance and narrow therapeutic windows
- Leveraging WuXiDARx™ technology for flexible DAR1-6 and WuXiTecan2™ hydrophilic linker, enabling streamlined dual-payload construction without antibody engineering
- Demonstrating a substantially wider therapeutic index alongside significantly enhanced anti-tumor efficacy in proof-of-concept studies
